Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the company’s stock in a transaction on Monday, July 13th. The stock was sold at an average price of $535.99, for a total value of $5,091,905.00. Following the completion of the sale, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $21,714,562.87. The trade was a 19.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

United Therapeutics Trading Up 1.0%

Shares of United Therapeutics stock opened at $531.79 on Thursday. United Therapeutics Corporation has a 12 month low of $272.12 and a 12 month high of $609.35. The firm has a market capitalization of $22.57 billion, a P/E ratio of 19.63, a P/E/G ratio of 1.76 and a beta of 0.58. The business has a fifty day simple moving average of $553.77 and a two-hundred day simple moving average of $529.94.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $6.63 earnings per share. Analysts predict that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Wall Street Analyst Weigh In

UTHR has been the topic of a number of analyst reports. Bank of America dropped their price target on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. TD Cowen reiterated a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Raymond James Financial initiated coverage on United Therapeutics in a research note on Friday, April 10th. They set an “outperform” rating and a $700.00 price objective for the company. Wells Fargo & Company raised United Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $575.00 to $735.00 in a research note on Thursday, May 7th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Ten equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $644.82.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently added to or reduced their stakes in UTHR. Leuthold Group LLC boosted its stake in shares of United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after buying an additional 3,126 shares during the last quarter. UBS Group AG increased its position in United Therapeutics by 45.3% during the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after acquiring an additional 70,445 shares during the last quarter. Perpetual Ltd bought a new position in United Therapeutics in the fourth quarter valued at about $1,059,000. SG Americas Securities LLC lifted its holdings in United Therapeutics by 88.6% in the fourth quarter. SG Americas Securities LLC now owns 26,960 shares of the biotechnology company’s stock valued at $13,136,000 after acquiring an additional 12,663 shares during the period. Finally, Brookstone Capital Management boosted its position in United Therapeutics by 25.4% in the fourth quarter. Brookstone Capital Management now owns 6,622 shares of the biotechnology company’s stock worth $3,227,000 after purchasing an additional 1,342 shares during the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.